9.73
-0.52 (-5.07%)
| Penutupan Terdahulu | 10.25 |
| Buka | 10.24 |
| Jumlah Dagangan | 959,501 |
| Purata Dagangan (3B) | 2,220,832 |
| Modal Pasaran | 622,916,928 |
| Harga / Jualan (P/S) | 5.84 |
| Harga / Buku (P/B) | 25.34 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2026 |
| Margin Keuntungan | -100.62% |
| Margin Operasi (TTM) | 13.62% |
| EPS Cair (TTM) | -3.09 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 469.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 48.70% |
| Nisbah Semasa (MRQ) | 2.93 |
| Aliran Tunai Operasi (OCF TTM) | -84.04 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -56.82 M |
| Pulangan Atas Aset (ROA TTM) | -17.56% |
| Pulangan Atas Ekuiti (ROE TTM) | -47.44% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | REGENXBIO Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -1.5 |
| Purata | -0.83 |
|
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 7.70% |
| % Dimiliki oleh Institusi | 87.65% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |